Testimony of Laura Lytle at the FDA Patient Engagement Device Advisory Committee Meeting

October 30, 2024: NCHR’s Laura Lytle testified at the FDA Patient Engagement Device Advisory Panel meeting in support of the FDA’s proposed guidance for informed consent, but suggested 4 key areas for improvement: using a short, simple checklist to ensure that patients understand the risks; focusing on informed consent as a process not a document; simple summaries of key information; and ensuring patient privacy.

The post Testimony of Laura Lytle at the FDA Patient Engagement Device Advisory Committee Meeting appeared first on National Center for Health Research.